AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04216693 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group will receive the digoxin-like placebo treatment.
Study NCT00960986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine hydrochloride
Description: po, QD
Study NCT03492814 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial wound closure
Description: 3 sutures distal to second molar and leaving the vertical releasing incision open without any sutures.
Study NCT03492814 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total wound closure
Description: 5 interrupted sutures with 2 sutures closing the vertical releasing incision and 3 sutures distal to second molar leading to a complete hermetic closure of the wound.
Study NCT02014233 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Study NCT02014233 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Study NCT00639444 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: gluten-free, normocaloric diet from 6 to 12 months
Description: Gluten-containing cereals (wheat, rye and barley) will be replaced by gluten-free starchy food (rice, corn, tapioca-based, etc) in a normocaloric diet
Study NCT03627338 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: questionaire, interview
Description: questionaire, interview
Study NCT03310801 — intervention group
Intervention type: PROCEDURE
Intervention: ACP or Watchman
Description: Left atrial appnedage occlusion using ACP or Watchman
Study NCT02171013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran polymorph I (≈ 83%) and polymorph II (≈17%)
Study NCT02171013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran polymorph I
Study NCT00921102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: 12.5 mg of a 5 mg/ml hyperbaric solution, intrathecally
Study NCT00921102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 12.5 mg of a 5 mg/ml hyperbaric solution, intrathecally
Study NCT00921102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 12.5 mg of a 5 mg/ml hyperbaric solution, intrathecally
Study NCT00921102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: 200 µg of a 200 µg/ml solution, intrathecally
Study NCT00921102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 200 µg of a 200 µg/ml solution, intrathecally
Study NCT00921102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 200 µg of a 200 µg/ml solution, intrathecally
Study NCT00921102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline solution
Description: 0.9% NaCl solution~0.1 ml, intrathecally in group Control and IV Atropine~0.1 ml, intravenously in group Control and Intrathecal Atropine
Study NCT00921102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline solution
Description: 0.9% NaCl solution~0.1 ml, intrathecally in group Control and IV Atropine~0.1 ml, intravenously in group Control and Intrathecal Atropine
Study NCT00921102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic saline solution
Description: 0.9% NaCl solution~0.1 ml, intrathecally in group Control and IV Atropine~0.1 ml, intravenously in group Control and Intrathecal Atropine
Study NCT00921102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: 100 µg of a 1 mg/ml preservative-free solution~* intrathecally in group Intrathecal Atropine~* intravenously in group IV Atropine
Study NCT00921102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: 100 µg of a 1 mg/ml preservative-free solution~* intrathecally in group Intrathecal Atropine~* intravenously in group IV Atropine
Study NCT01302444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Tadalafil 40mg for 12 weeks
Study NCT01302444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 12 weeks
Study NCT03645746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5069
Description: REGN5069 will be administered by IV infusion or SC injection
Study NCT03645746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching REGN5069
Study NCT03922737 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: In-person office visit
Description: Post-operative visit to occur in-person with provider
Study NCT03922737 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Teleheath visit
Description: Post-operative visit to occur via telehealth software platform with provider
Study NCT04306744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vorso PROTECT System
Description: The Vorso PROTECT System is designed to deliver targeted, imperceptible, non-invasive stimulation to the ear to treat the signs and symptoms (e.g., tender and swollen joints, pain, synovitis) of patients with rheumatoid arthritis.
Study NCT04306744 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Vorso PROTECT System - Sham (OFF)
Description: Identical device to experimental arm, but the device will not deliver stimulation
Study NCT02838719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perineural Dexamethasone acetate
Study NCT02838719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous dexamethasone acetate
Study NCT00444041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: neoadjuvant therapy prior to elective surgery
Study NCT04025775 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CamAPS HX Closed-loop
Description: The CamAPS HX closed-loop system comprises~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump~* Glooko/Diasend cloud upload system to monitor CGM/insulin data.
Study NCT04025775 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multiple Daily Insulin Injections (Control)
Description: Multiple Daily Insulin Injections with masked Dexcom G6 CGM sensor (Dexcom, Northridge, CA, USA)
Study NCT03692793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: Patients will perform continuous aerobic training (treadmill walking) during 30min (60% of the 6MWT mean speed) and progression according to dyspnea (4-6 of the modified Borg scale). Upper limbs resistance training will be performed using the modified diagonals from the proprioceptive neuromuscular facilitation method (2 sets of 2min). Lower limbs strength training will be performed for quadriceps and triceps sural (2 sets of 10 repetitions), with progression when the patients report that the exercise are ´easy´. All the muscle exercised and the breathing accessory muscles will be stretched for 30s. Eleven educational sessions will be delivered addressing topics related to COPD self-management.
Study NCT00416130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: MK-0683 capsules, 100 mg, 400mg once a day, continuously (at dose level 0 - Phase 1 part of the study)
Study NCT02562222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anodal tDCS on M1
Description: The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds.
Study NCT02562222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cathodal tDCS on M1
Description: The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds.
Study NCT02562222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anodal tDCS on V1
Description: The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds.
Study NCT02562222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cathodal tDCS on V1
Description: The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds.
Study NCT02562222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anodal tDCS on M1 and cathodal on V1
Description: The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds.
Study NCT02562222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cathodal tDCS on M1 and anodal on V1
Description: The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds.
Study NCT02562222 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds.
Study NCT03962790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-DAY ACUVUE® MOIST
Description: etafilcon A contact lenses made with a new manufacturing technology
Study NCT03962790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-DAY ACUVUE® MOIST
Description: etafilcon A contact lenses made with the current manufacturing technology
Study NCT00774553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Dose titration of oral suspension to a tolerable dose given twice daily for 10 days.
Study NCT00774553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose titration of oral suspension to a tolerable dose given twice daily for 10 days.
Study NCT04535531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB206 10.3% berdazimer
Description: Topically once daily
Study NCT04535531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle gel
Description: Topically once daily
Study NCT03579186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OKS
Description: Optokinetic stimulation
Study NCT02993952 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned area C3 for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode. A constant current of 2mA will be applied for 20 minutes.
Study NCT02993952 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned area C3 for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode, but the stimulator was turned off after 30 seconds of stimulation. Therefore, patients in the sham group felt the initial itching sensation but received no current for the rest of the stimulation period.
Study NCT04424082 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Removal of dead space filter
Description: Dead space filters will be removed and Vcap parameters (VCO2 ml/min, PaCO2 kPa, alveolar dead space in ml) recorded before and after removal
Study NCT00381043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acamprosate (Campral)
Description: The study is a double-blind, randomized, placebo-controlled clinical trial in which participants will receive 333 mg t.i.d. oral acamprosate or matching placebo for a 12-week period. Each participant will also receive brief behavioral intervention at each visit.
Study NCT00381043 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acamprosate (Campral)
Description: The study is a double-blind, randomized, placebo-controlled clinical trial in which participants will receive 333 mg t.i.d. oral acamprosate or matching placebo for a 12-week period. Each participant will also receive brief behavioral intervention at each visit.
Study NCT01028079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: Aspirin 1000 mg (solid dose caplet) to be given three times daily as for 2 consecutive days (48 hours), followed by Aspirin 1000 mg (solid dose caplet) to be taken as per need, but not more than three times daily for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 3000 mg Aspirin.
Study NCT01028079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 400 mg caplet to be given three times a day as for 2 consecutive days (48 hours), followed by ibuprofen 400 mg caplet to be given as per need, but not more than three times a day for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 1200 mg ibuprofen.
Study NCT01028079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (two placebos: Placebo Aspirin and Placebo Ibuprofen) to be given three times a day for a maximum of 5 consecutive days in the same regimen as for Experimental Drug and Active Comparator.
Study NCT03948087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum Removable Rigid Dressing (VRRD)
Description: Intra-operative application of device.
Study NCT02120664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetapir (18F)
Study NCT02120664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-PiB
Study NCT02058290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV morphine sulfate or Sponsor-approved equivalent
Description: Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to a floor if the stay in the PACU is less than one hour.
Study NCT02058290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL
Description: Patients will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 40 cc administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed.
Study NCT03923010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Participants will receive itraconazole 200 mg orally once daily for 7 days and at the discretion of the treating physician on Day 14. Participants will also get their regular clinical care at the discretion of their treating physician.
Study NCT02379065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Aerogen Aeroneb Solo©
Study NCT02379065 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phillips Respironic© mask
Study NCT01629056 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ablation
Description: RF ablation to the left atrium of the heart, guided by ECI-contact information (active arm)
Study NCT01629056 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: RF ablation
Description: RF ablation to the left atrium of the heart, without the use of ECI-contact information (control arm)
Study NCT00315588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islet Transplantation
Description: Islet Transplantation in subjects with a previous kidney transplant.
Study NCT04121039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
Study NCT04121039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib
Description: Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
Study NCT04121039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: POF
Description: The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
Study NCT01761539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aggressive Hydration
Description: Receives 20cc/kg bolus and 3cc/kg/hr thereafter.
Study NCT01761539 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Hydration
Description: Receives 10cc/kg bolus and 1.5cc/kg/hr thereafter.